Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
暂无分享,去创建一个
H. Dombret | A. Stamatoullas | S. Chevret | E. Wattel | P. Fenaux | M. Sébert | L. Adès | C. Gardin | C. Récher | N. Vey | E. Raffoux | T. Prebet | M. Hunault | A. Toma | K. Bouabdallah | L. Stalnikiewicz | C. Chaffaut | R. Guièze